Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Rawson, Nigel S B ^a,b   Terres, Jorge A Ross ^a  

^a GLAXOSMITHKLINE   (Canada)

^b Eastlake Research Group   (Canada)

Author keywords

Adverse events; Prescription data; Risk communication; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ROSIGLITAZONE;

ARTICLE; CANADA; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; HUMAN;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CANADA; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

MLCS; MLOWN;

EID: 84874461238     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-82     Document Type: Article

References (11)

1. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Nissen SE, Wolski K, N Engl J Med 2007 356 2457 2471 10.1056/NEJMoa072761 17517853 (Pubitemid 46919772)
2. Temporal trends in anti-diabetes drug use in tricare following safety warnings in 2007 about rosiglitazone. Stewart KA, Natzke BM, Williams T, Granger E, Casscells SW, Croghan TW, Pharmacoepidemiol Drug Saf 2009 18 1048 1052 10.1002/pds.1819 19655338
3. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. Starner CI, Schafer JA, Heaton AH, Gleason PP, J Manag Care Pharm 2008 14 523 531 18693776
4. Changes in glitazone use among office-based physicians in the US, 2003-2009. Cohen A, Rabbani A, Shah N, Alexander GC, Diabetes Care 2010 33 823 825 10.2337/dc09-1834 20103549
5. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Ruiter R, Visser LE, van Herk-Sukel MPP, Geelhoed-Duijvestijn PH, de Bie S, Straus SMJM, Mol PGM, Romio SA, Herings RMC, Stricker BHC, Drug Saf 2012 35 471 480 10.2165/11596950-000000000-00000 22540371
6. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Shah BR, Juurlink DN, Austin PC, Mamdani MM, Diab Med 2008 25 871 874 10.1111/j.1464-5491.2008.02462.x
7. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR, Open Med 2010 4 50 21686295
8. Health Canada endorsed important safety information on rosiglitazone Ottawa: Health Canada 2007 http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories- avis/prof/-2007/avandia-hpc-cps-5-eng.php (accessed: 18 Dec 2012)
9. IMS Brogan. Longitudinal (LRx) insights (part of Lifelink) Mississauga, ON: IMS Health Inc 2012 http://imsbrogansolutions.com/main.php?t=services&i= 15 (accessed: 18 Dec 2012)
10. Morgan SG, Raymond C, Mooney D, Martin D, The Canadian Rx Atlas Vancouver: Centre for Health Services and Policy Research 2 2008
11. Database size and power to detect safety signals in pharmacovigilance. Hammond IW, Gibbs TG, Seifert HA, Rich DS, Expert Opin Drug Saf 2007 6 713 721 10.1517/14740338.6.6.713 17967160 (Pubitemid 351308283)